BACKGROUND: Highly active antiretroviral therapy (HAART) has improved the survival of patients with acquired immunodeficiency syndrome-related lymphoma (ARL). The German ARL Study Group investigated whether HAART administered concomitantly with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy compromised the course of immune parameters during and after chemotherapy and exerted a positive effect on remission and survival. METHODS: From 1997 to 2001, 72 patients with ARL were stratified prospectively into a standard-risk group (n = 48 patients) and a high-risk group (n = 24 patients) with either 0-1 or 2-3 of the following risk factors: CD4 < 50/microL, prior opportunistic infection, and/or a World Health Organization performance status > or = 3. Patients in the high-risk group received > or =75% of the CHOP regimen. RESULTS: In the standard-risk group (CD4 = 223/muL; age-adjusted International Prognostic Index [aaIPI], 38% > or = 2), the complete remission (CR) rate was 79%, and median survival was not reached after a median 47 months of follow-up. CD4 counts did not change from baseline to 4 weeks after the end of chemotherapy (206/microL). In the high-risk group (CD4 = 34/muL; aaIPI, 88% > or = 2), the CR rate was 29%, and the median survival was 7.2 months (3 patients survived for > 3 yrs). Toxicity was moderate: Leukopenia Grade 3 or 4 occurred in 100 of 249 chemotherapy cycles (40%) in the standard-risk group and in 70 of 102 cycles (69%) in the high-risk group. CONCLUSIONS: Based on the aaIPI, the survival of patients in the standard-risk group was very similar to that achieved by nonhuman immunodeficiency virus-infected patients who had aggressive lymphomas. Concurrent CHOP plus HAART can be administered in an outpatient setting. Thus, the authors recommend using this modality as first-line therapy for patients with ARL. Copyright 2006 American Cancer Society.
BACKGROUND: Highly active antiretroviral therapy (HAART) has improved the survival of patients with acquired immunodeficiency syndrome-related lymphoma (ARL). The German ARL Study Group investigated whether HAART administered concomitantly with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy compromised the course of immune parameters during and after chemotherapy and exerted a positive effect on remission and survival. METHODS: From 1997 to 2001, 72 patients with ARL were stratified prospectively into a standard-risk group (n = 48 patients) and a high-risk group (n = 24 patients) with either 0-1 or 2-3 of the following risk factors: CD4 < 50/microL, prior opportunistic infection, and/or a World Health Organization performance status > or = 3. Patients in the high-risk group received > or =75% of the CHOP regimen. RESULTS: In the standard-risk group (CD4 = 223/muL; age-adjusted International Prognostic Index [aaIPI], 38% > or = 2), the complete remission (CR) rate was 79%, and median survival was not reached after a median 47 months of follow-up. CD4 counts did not change from baseline to 4 weeks after the end of chemotherapy (206/microL). In the high-risk group (CD4 = 34/muL; aaIPI, 88% > or = 2), the CR rate was 29%, and the median survival was 7.2 months (3 patients survived for > 3 yrs). Toxicity was moderate: Leukopenia Grade 3 or 4 occurred in 100 of 249 chemotherapy cycles (40%) in the standard-risk group and in 70 of 102 cycles (69%) in the high-risk group. CONCLUSIONS: Based on the aaIPI, the survival of patients in the standard-risk group was very similar to that achieved by nonhuman immunodeficiency virus-infectedpatients who had aggressive lymphomas. Concurrent CHOP plus HAART can be administered in an outpatient setting. Thus, the authors recommend using this modality as first-line therapy for patients with ARL. Copyright 2006 American Cancer Society.
Authors: Mark Manak; Silvana Sina; Bharathi Anekella; Indira Hewlett; Eric Sanders-Buell; Viswanath Ragupathy; Jerome Kim; Marion Vermeulen; Susan L Stramer; Ester Sabino; Piotr Grabarczyk; Nelson Michael; Sheila Peel; Patricia Garrett; Sodsai Tovanabutra; Michael P Busch; Marco Schito Journal: AIDS Res Hum Retroviruses Date: 2012-02-24 Impact factor: 2.205
Authors: Ulas Darda Bayraktar; Luis A Diaz; Brittany Ashlock; Ngoc Toomey; Lisa Cabral; Soley Bayraktar; Denise Pereira; Dirk P Dittmer; Juan Carlos Ramos Journal: Leuk Lymphoma Date: 2013-08-28
Authors: Stefan K Barta; Xiaonan Xue; Dan Wang; Roni Tamari; Jeannette Y Lee; Nicolas Mounier; Lawrence D Kaplan; Josep-Maria Ribera; Michele Spina; Umberto Tirelli; Rudolf Weiss; Lionel Galicier; Francois Boue; Wyndham H Wilson; Christoph Wyen; Albert Oriol; José-Tomás Navarro; Kieron Dunleavy; Richard F Little; Lee Ratner; Olga Garcia; Mireia Morgades; Scot C Remick; Ariela Noy; Joseph A Sparano Journal: Blood Date: 2013-09-06 Impact factor: 22.113
Authors: Gita Suneja; Meredith S Shiels; Rory Angulo; Glenn E Copeland; Lou Gonsalves; Anne M Hakenewerth; Kathryn E Macomber; Sharon K Melville; Eric A Engels Journal: J Clin Oncol Date: 2014-06-30 Impact factor: 44.544
Authors: Thomas R Spitzer; Richard F Ambinder; Jeannette Y Lee; Lawrence D Kaplan; William Wachsman; David J Straus; David M Aboulafia; David T Scadden Journal: Biol Blood Marrow Transplant Date: 2008-01 Impact factor: 5.742